A prospective, randomized, controlled study of rivaroxaban in the prevention of venous thrombosis in patients with deep vein catheterization chemotherapy for breast cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031649

Enrollment

Unknown

Registered

2020-04-06

Start date

2020-04-05

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thrombosis of breast cancer

Interventions

Experimental group:rivaroxaban 10mg.po.qd

Control group:Without preventive anticoagulant

Eligibility

Sex/Gender

Female

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Breast cancer patients diagnosed by histopathology; 2. Breast cancer patients with PICC catheterization or subclavian vein catheterization chemotherapy; 3. aged >18 years old, ECOG score 0-2 points; 4. the main organ function is acceptable (bone marrow, heart, liver, lung, kidney, etc.); 5. the life expectancy is greater than 3 months.

Exclusion criteria

Exclusion criteria: 1. Patients with rivaroxaban allergy; 2. non-breast cancer patients; 3. patients with thrombolytic or anticoagulant therapy;Patients with active bleeding tendency, hemophilia, thrombocytopenia, or hypersplenism; 4. important organ function is incomplete or serious heart disease patients, including: congestive heart failure, arrhythmia, uncontrolled hypertension, etc.; 5. breast cancer combined with other types of malignant tumors; 6. Pregnant or lactating female patients; 7. patients without signed informed consent.

Design outcomes

Primary

Measure	Time frame
Catheter-related venous thrombus;	—

Countries

China

Contacts

Public ContactDie Sang

Beijing Chaoyang District San Huan Cancer Hospital

sangdie0123@126.com+86 135 5223 4679

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026